Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products
- 1 January 2008
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (1) , 259-268
Abstract
Small unilamellar amphotericin B liposomes can reduce the toxicity of amphotericin B. In this study, we compared the physical, antifungal, pharmocokinetic, and toxic properties of two liposomal amphotericin B products, AmBisome and Anfogen, that have the same chemical composition but are manufactured differently. In vitro tests included determinations of the MICs and the concentrations causing the release of 50% of the intracellular potassium from red blood cells (K50values) to assess toxicity. The 50% lethal dose (LD50) was evaluated by using uninfected C57BL/6 mice and single intravenous (i.v.) doses of 1 to 100 mg/kg of body weight. Multiple i.v. dosing over 18 days was performed with 0.5, 1.0, or 5.0 mg of Anfogen/kg or 1.0, 5.0, or 25 mg of AmBisome/kg to evaluate chronic toxicity. DBA/2 mice were infected intranasally with 2.5 × 106Aspergillus fumigatusconidia, treated for 3 or 4 days with 3.0, 5.0, or 7.5 mg of Anfogen/kg or 3, 5, 7.5, or 15 mg of AmBisome/kg, and evaluated to assess the toxicity of the drugs to the kidneys (by measurement of blood urea nitrogen and creatinine levels and histopathology) and the drug efficacy. The median particle size was 77.8 nm for AmBisome and 111.5 nm for Anfogen. In vitro K50values were significantly lower for Anfogen (0.9 μg/ml) than for AmBisome (20 μg/ml), and the LD50of AmBisome was >100 mg/kg, versus 10 mg of Anfogen/kg. There was significant renal tubular necrosis in uninfected and infected mice given Anfogen but no tubular necrosis in AmBisome-treated mice. AmBisome at 7.5 or 15 mg/kg was also more efficacious than 7.5 mg of Anfogen/kg for the treatment of pulmonary aspergillosis, based on survival and weight loss data and numbers of CFU per gram of lung. In conclusion, the efficacy and toxicity of these two liposomal amphotericin B products were significantly different, and thus, the products were not comparable.Keywords
This publication has 37 references indexed in Scilit:
- Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)Clinical Infectious Diseases, 2007
- Process Development and Quality Control of Injectable Liposomal Therapeutics2006
- Comparative Efficacies, Toxicities, and Tissue Concentrations of Amphotericin B Lipid Formulations in a Murine Pulmonary Aspergillosis ModelAntimicrobial Agents and Chemotherapy, 2006
- Efficacies of Amphotericin B (AMB) Lipid Complex, AMB Colloidal Dispersion, Liposomal AMB, and Conventional AMB in Treatment of Murine CoccidioidomycosisAntimicrobial Agents and Chemotherapy, 2004
- Efficacy of Intravenous Liposomal Amphotericin B (AmBisome) against Coccidioidal Meningitis in RabbitsAntimicrobial Agents and Chemotherapy, 2002
- Clearance of Fungal Burden during Treatment of Disseminated Histoplasmosis with Liposomal Amphotericin B versus ItraconazoleAntimicrobial Agents and Chemotherapy, 2001
- Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in ExperimentalCandida albicansInfection of the Central Nervous SystemThe Journal of Infectious Diseases, 2000
- Determination of the Relative Toxicity of Amphotericin B Formulations: A Red Blood Cell Potassium Release AssayDrug Delivery, 1999
- Efficacy of Unilamellar Liposomal Amphotericin B in Treatment of Pulmonary Aspergillosis in Persistently Granulocytopenic Rabbits: The Potential Role of Bronchoalveolar D-Mannitol and Serum Galactomannan as Markers of InfectionThe Journal of Infectious Diseases, 1994
- Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosisJournal of Antimicrobial Chemotherapy, 1994